2025年6月8日 周日
Home > Archive>Volume 29, Issue 4, 2021 >353-358
PDF HTML XML Export Cite reminder
Research progress of liver transplantation for patients with homozygous familial hypercholesterolemia
Author:
Affiliation:

Chinese Academy of Medical Sciences & Peking Union Medical College & Endocrinology and Cardiovascular Metabolism Center, Fuwai Hospital, Beijing 100037, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [41]
    • | |
  • Cited by
    • | |
  • Comments
    Abstract:

    Familial hypercholesterolemia (FH) is an autosomal dominant inherited metabolic disorder, patient with FH has an elevated serum low density lipoprotein cholesterol(LDLC) and a high incidence of premature atherosclerotic cardiovascular disease (ASCVD). If untreated, patients with homozygous familial hypercholesterolemia (HoFH) develop premature death by the age of 30 years, generally from ASCVD. Cholesterol-lowing therapies for HoFH include therapeutic lifestyle changes, lipid-lowing pharmacologic therapy, lipid apheresis and liver transplantation, etc. However, the curative effect of the traditional lipid-lowering drugs is still very limited in HoFH population. It is difficult to carry out lipid apheresis constantly because of its high cost, invasiveness, long-term maintenance at weekly or biweekly interval and poor adherence. Nearly 90% of FH is caused by mutations in the LDL receptor (LDLR) gene. Since LDLR are located mainly in the hepatocytes, liver transplantation achieves the replacement of dysfunctional hepatic LDLR, and it is considered to be the effective way to correct hepatic cholesterol metabolism. This paper mainly review the efficacy and safety of liver transplantation, current challenges and the prospect of liver transplantation for HoFH.

    Reference
    [1] Brautbar A, Leary E, Rasmussen K, et al.Genetics of familial hypercholesterolemia.Curr Atheroscler Rep, 5,7(4):491.
    [2] Benn M, Watts GF, Tybjrg-Hansen A, et al.Mutations causative of familial hypercholesterolaemia:screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.Eur Heart J, 6,7(17):1384-1394.
    [3] Sjouke B, Kusters DM, Kindt I, et al.Homozygous autosomal dominant hypercholesterolaemia in the Netherlands:prevalence, genotype-phenotype relationship, and clinical outcome.Eur Heart J, 5,6(9):560-565.
    [4] Cuchel M.Bruckert E, Ginsberg HN, et al.Homozygous familial hypercholesterolaemia:new insights and guidance for clinicians to improve detection and clinical management.A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.Eur Heart J, 4,5(32):2146-2157.
    [5] Ference BA, Ginsberg HN, Graham I, et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease.1.Evidence from genetic, epidemiologic, and clinical studies.A consensus statement from the European Atherosclerosis Society Consensus Panel.Eur Heart J, 7,8(32):2459-2472.
    [6] Gagné C, Gaudet D, Bruckert E, et al.Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.Circulation, 2,5(21):2469-2475.
    [7] Raal FJ, Honarpour N, Blom DJ, et al.Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B):a randomised, double-blind, placebo-controlled trial.Lancet, 5,5(9965):341-350.
    [8] Raal FJ, Hovingh GK, Blom D, et al.Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia:an interim subset analysis of the open-label TAUSSIG study.Lancet Diabetes Endocrinol, 7,5(4):280-290.
    [9] Stein EA, Honarpour N, Wasserman SM, et al.Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.Circulation, 3,8(19):2113-2120.
    [10] Cuchel M, Bloedon LT, Szapary PO, et al.Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.N Engl J Med, 7,6(2):148-156.
    [11] Raal FJ, Santos RD, Blom DJ, et al.Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia:a randomised, double-blind, placebo-controlled trial.Lancet, 0,5(9719):998-1006.
    [12] Makino H, Koezuka R, Tamanaha T, et al.Familial hypercholesterolemia and lipoprotein apheresis.J Atheroscler Thromb, 9,6(8):679-687.
    [13] Wang A, Richhariya A, Gandra SR, et al.Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia.J Am Heart Assoc, 6,5(7):e003294.
    [14] Sampietro T.The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis, Atheroscler Suppl.2015:268-272.
    [15] Bilheimer, WD, Goldstein JL, Grundy SM, et al.Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.N Engl J Med, 4,1(26):1658-1664.
    [16] Starzl TE, Bilheimer DW, Bahnson HT, et al.Heart-liver transplantation in a patient with familial hypercholesterolaemia.Lancet, 4,1(8391):1382-1383.
    [17] Gulsoy KN, Kirnap M, Bascil TN, et al.The curative treatment of familial hypercholesterolemia:Liver transplantation.Clin Transplant, 9,3(12):e13730.
    [18] Ibrahim M, El-Hamamsy I, Barbir M, et al.Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively.J Cardiovasc Transl Res, 2,5(3):351-358.
    [19] Ishigaki Y, Kawagishi N, Hasegawa Y, et al.Liver transplantation for homozygous familial hypercholesterolemia.J Atheroscler Thromb, 9,6(2):121-127.
    [20] Offstad J, Schrumpf E, Geiran O, et al.Plasma exchange and heart-liver transplantation in a patient with homozygous familial hypercholesterolemia.Clin Transplant, 1,5(6):432-436.
    [21] Kawagishi N, Satoh K, Akamatsu Y, et al.Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor.J Atheroscler Thromb, 7,4(2):94-98.
    [22] Khalifeh M, Faraj W, Heaton N, et al.Successful living-related liver transplantation for familial hypercholesterolemia in the Middle East.Transpl Int, 5,7(11):735-739.
    [23] Revell SP, Noble-Jamieson G, Johnston P, et al.Liver transplantation for homozygous familial hypercholesterolaemia.Arch Dis Child, 5,3(5):456-458.
    [24] Kakaei F, Nikeghbalian S, Kazemi K, et al.Liver transplantation for homozygous familial hypercholesterolemia:two case reports.Transplant Proc, 9,1(7):2939-2941.
    [25] Adam, R.Evolution of indications and results of liver transplantation in Europe.A report from the European Liver Transplant Registry(ELTR).J Hepatol, 2,7(3):675-688.
    [26] Küükkartallar T, Yankol Y, Kanmaz T, et al.Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia.Pediatr Transplant, 1,5(3):281-284.
    [27] Moyle M, Tate B.Homozygous familial hypercholesterolaemia presenting with cutaneous xanthomas:response to liver transplantation.Australas J Dermatol, 4,5(4):226-228.
    [28] Maiorana A, Nobili V, Calandra S, et al.Preemptive liver transplantation in a child with familial hypercholesterolemia.Pediatr Transplant, 1,5(2):E25-E29.
    [29] Schmidt, HH.Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous pW577R LDL-receptor gene mutation.Clin Transplant, 8,2(2):180-184.
    [30] Cephus CE, Qureshi AM, Sexson Tejtel SK, et al.Coronary artery disease in a child with homozygous familial hypercholesterolemia:regression after liver transplantation.J Clin Lipidol, 9,3(6):880-886.
    [31] Page MM, Ekinci EI, Jones RM, et al.Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.Intern Med J, 4,4(6):601-604.
    [32] Martinez M, Brodlie S, Griesemer A, et al.Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia.Am J Cardiol, 6,8(4):504-510.
    [33] Alim A, Tokat Y, Erdogan Y, et al.Liver transplantation for homozygote familial hypercholesterolemia:the only curative treatment.Pediatr Transplant, 6,0(8):1060-1064.
    [34] Hackl C, Schlitt HJ, Melter M, et al.Current developments in pediatric liver transplantation.World J Hepatol, 5,7(11):1509-1520.
    [35] Ng VL, Fecteau A, Shepherd R, et al.Outcomes of 5-year survivors of pediatric liver transplantation:report on 461 children from a North American multicenter registry.Pediatrics, 8,2(6):e1128-e1135.
    [36] Mansoorian M, Kazemi K, Nikeghbalian S, et al.Liver transplantation as a definitive treatment for familial hypercholesterolemia:a series of 36 cases.Pediatr Transplant, 5,9(6):605-611.
    [37] Kasahara M, Umeshita K, Inomata Y, et al.Long-term outcomes of pediatric living donor liver transplantation in Japan:an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society.Am J Transplant, 3,3(7):1830-1839.
    [38] Kasahara M, Umeshita K, Sakamoto S, et al.Living donor liver transplantation for biliary atresia:an analysis of 2 085 cases in the registry of the Japanese Liver Transplantation Society.Am J Transplant, 8,8(3):659-668.
    [39] Pan ZY, Yc F, Wang XQ, et al.Pediatric living donor liver transplantation decade progress in Shanghai:characteristics and risks factors of mortality.World J Gastroenterol, 0,6(12):1352-1364.
    [40] De La Fuente S, Citores MJ, Baos I, et al.Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events:analysis of 30 cases.Transplant Proc, 4,6(9):3111-3113.
    [41] Kamath BM, Olthoff KM.Liver transplantation in children:update 2010.Pediatr Clin North Am, 0,7(2):401-414.
    Related
    Cited by
Get Citation

ZHAO Liang, WEN Jun, GUO Yuanlin. Research progress of liver transplantation for patients with homozygous familial hypercholesterolemia[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(4):353-358.

Copy
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:July 03,2020
  • Revised:December 30,2020
  • Online: April 14,2021
Article QR Code

You are the 55923 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025